Methods of treating cancer by targeting tumor-associated macrophages
US-2024415921-A1 · Dec 19, 2024 · US
US9457058B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9457058-B2 |
| Application number | US-201414513584-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 14, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
Opening claim text (preview).
What is claimed is: 1. A nutritional composition, comprising: (i) a carbohydrate source; (ii) a fat source; and (iii) a protein equivalent source; wherein a) 20% to 80% of the protein equivalent source includes a peptide component comprising the following peptides: SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 32 SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63; further wherein the peptide component comprises at least 3 additional individual peptides selected from Table 1; and b) 20% to 80% of the protein equivalent source comprises an intact protein and a partially hydrolyzed protein. 2. The nutritional composition of claim 1 , comprising at least 10 additional peptides selected from Table 1. 3. The nutritional composition of claim 1 , wherein the protein equivalent source comprises casein hydrolysate having a molar mass distribution of greater than 500 Daltons. 4. The nutritional composition of claim 1 , wherein the protein equivalent source comprises partially hydrolyzed protein having a degree of hydrolysis of less than 40%. 5. The nutritional composition of claim 1 , further comprising a prebiotic. 6. The nutritional composition of claim 1 , further comprising a culture supernatant from a late-exponential growth phase of a probiotic batch-cultivation process. 7. The nutritional composition of claim 1 wherein the peptide component is present in an amount of from about 0.2 g/100 kcals to about 5.6 g/100 kcals. 8. The nutritional composition of claim 1 , further comprising β-glucan. 9. The nutritional composition of claim 1 , further comprising a probiotic. 10. The nutritional composition of claim 1 , further comprising at least one long-chain polyunsaturated fatty acid, wherein the at least one long-chain polyunsaturated fatty acid is selected from the group consisting of docosahexaenoic acid and arachidonic acid. 11. A nutritional composition comprising per 100 kcals: (i) from about 5 g to about 25 g of a carbohydrate source; (ii) from about 1.3 g to about 7.2 g of a fat source; and (iii) from about 1 g to about 7 g of a protein equivalent source; wherein a) 20% to 80% of the protein equivalent source comprises a peptide component comprising the following peptides: SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 32 SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63; wherein the peptide component further comprises at least 3 additional individual peptides selected from Table 1; and b) at least 20% of the protein equivalent source comprises a casein hydrolysate having a molar mass distribution of greater than 500 Daltons. 12. The nutritional composition of claim 11 , wherein the peptide component further comprises at least 10 additional individual peptides selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 33, SEQ ID NO 34, SEQ ID NO 35, SEQ ID NO 36, SEQ ID NO 37, SEQ ID NO 38, SEQ ID NO 39, SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 52, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 61, SEQ ID NO 62, and SEQ ID NO 64. 13. The nutritional composition of claim 11 , further comprising at least one long-chain polyunsaturated fatty acid. 14. The nutritional composition of claim 11 , further comprising at least one probiotic. 15. The nutritional composition of claim 11 , further comprising at least one prebiotic. 16. The nutritional composition of claim 11 , further comprising β-glucan.
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Tripeptides · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.